Hypertension Treatment
Hypertension Treatment - Related Videos
01:28
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
0 Views •
2024
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH). Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
01:18
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
0 Views •
2024
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists. ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
01:23
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
0 Views •
2024
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body. These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:16
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
0 Views •
2024
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home. Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue, improving...
06:34
Laser-Induced Chronic Ocular Hypertension Model on SD Rats
0 Views •
Cited by 26 •
2007
Glaucoma is one of the major causes of blindness in the world. Elevated intraocular pressure is a major risk factor. Laser photocoagulation induced ocular hypertension is one of the well established animal models. This video demonstrates how to induce ocular hypertension by Argon laser photocoagulation in rat.
FAQs
Reducing sodium and fluid retention lowers the amount of fluid contributing to blood volume. This mechanism addresses one component of persistently elevated pressure and can complement therapies that act on vascular resistance or hormonal signaling. Its relevance is greatest when treatment planning considers the different physiological factors that sustain high blood pressure rather than relying on a single mechanism.
Vascular smooth muscle relaxation primarily targets vascular resistance, allowing the vessels to oppose blood flow less strongly. Limiting renin-angiotensin-aldosterone system signals addresses pathways that increase both vascular resistance and blood volume. These distinct actions explain why clinicians may select therapies with different mechanisms or combine them when one approach does not provide adequate control.
Blood pressure levels, coexisting conditions, treatment response, and potential adverse effects guide the choice between a single mechanism and a combination of therapies. Combining agents can address more than one contributor to elevated pressure, while treatment response and adverse effects determine whether the regimen remains appropriate. This individualized selection supports sustained control and safer prescribing.
Clinicians begin by considering the patient’s blood pressure level and relevant coexisting conditions, then select lifestyle measures, medical therapy, or both. They evaluate the treatment response and potential adverse effects as therapy continues. If control is insufficient or tolerability is a concern, the regimen can be adjusted or combined with another approach to improve the overall balance of benefit and risk.
They are considered together when lowering blood pressure requires more than one complementary approach. Lifestyle measures provide a non-drug component, while medical therapies can target sodium and fluid retention, vascular smooth muscle, or renin-angiotensin-aldosterone system signaling. Using both allows treatment planning to address several contributors to elevated pressure and supports the broader goal of reducing future organ-related risks.
The broader aim is to reduce the risk of stroke, heart disease, and kidney damage associated with persistently elevated blood pressure. Pharmacological understanding helps clinicians connect a drug’s mechanism with these prevention goals, select rational combinations, and respond to treatment results. This perspective also supports development of therapies designed to provide safer and more effective long-term control.